Evidence map›Paper›PMID 31581738›Full record

ReviewJournal of clinical medicine2019

Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.

Valli De Re, Laura Caggiari, Ombretta Repetto, Lara Mussolin, Maurizio Mascarin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. PD1.5 variant onAmerican journal of clinical and experimental urology · 2022
    Article
  9. Article
  10. Barriers to achieving a cure in lymphoma.Cancer drug resistance (Alhambra, Calif.) · 2021
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Valli De ReImmunopathology and Tumour Biomarkers Unit/Bio-proteomics Facility, Department of Research and Advanced Tumour Diagnostics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, 33081 Aviano, Italy. vdere@cro.it.
Laura CaggiariImmunopathology and Tumour Biomarkers Unit/Bio-proteomics Facility, Department of Research and Advanced Tumour Diagnostics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, 33081 Aviano, Italy. lcaggiari@cro.it.
Ombretta RepettoImmunopathology and Tumour Biomarkers Unit/Bio-proteomics Facility, Department of Research and Advanced Tumour Diagnostics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, 33081 Aviano, Italy. orepetto@cro.it.
Lara MussolinClinic of Paediatric Haemato-Oncology, Department of Women's and Children's Health, University of Padua, 35127 Padua, Italy. lara.mussolin@unipd.it.
Maurizio MascarinPediatric Radiotherapy and AYA Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. mascarin@cro.it.

Funding

the BCC Banca di. Credito Cooperativo Pordenonese and the CRO 5X1000_2010_MdS, Italy. CRO 5X1000_2010_MdS
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adverse eventsangiogenesiscytokinesEBVextracellular vesiclesHodgkin lymphomaimmune checkpoint inhibitorsPD-1PD-L1

Identifiers

PMID31581738
PMCPMC6832444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.